Pricing Log in Create free account

AgomAb Therapeutics NV (AGMB) vs Lyell Immunopharma, Inc. (LYEL)

AgomAb Therapeutics NV and Lyell Immunopharma, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. is the larger, with a market value of $411.8M against $344.3M — 1.2× the size. Across the 7 metrics below, AgomAb Therapeutics NV leads on 4 and Lyell Immunopharma, Inc. on 3.

Valuation

Metric AGMB LYEL Biotechnology median
P/E — n/m 10.96
P/S — 27,335.74 9.52
P/B n/m 2.13 2.23
Price to free cash flow n/m n/m 25.69
EV/EBITDA n/m n/m 0.68
EV/Sales n/m 15,528.67 9.00
Earnings yield — (74.87%) (32.09%)
Free cash flow yield 0.00% (44.17%) (22.62%)

Profitability

Metric AGMB LYEL Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin — (1,783,580.00%) 0.00%
Net margin — (1,701,066.67%) 0.00%
Free cash flow margin 0.00% (1,207,540.00%) 0.00%
Return on equity — (97.79%) (50.12%)
Return on assets — (74.85%) (45.12%)
Return on invested capital 0.00% (1,070.83%) 0.00%

Growth

Metric AGMB LYEL Biotechnology median
Revenue growth (TTM) — (63.41%) 6.78%
EPS growth (last fiscal year) (39.80%) 38.70% 29.88%
Revenue growth, 5-year CAGR — (65.85%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AGMB LYEL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.88 4.02 4.74
Net debt to EBITDA 1.96 0.94 1.01

Dividend

Metric AGMB LYEL Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric AGMB LYEL Biotechnology median
Market cap 344.26m 411.81m 166.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack